ELX-02 (NB124) developed by Eloxx Pharmaceuticals (Waltham, MA, USA) has been shown to restore CFTR function in pre-clinical models examining the compound as read-through agent for CF caused by the G542X mutation [16,17]. This evidence concerns the gene CFTR and cystic fibrosis.